You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

56 Results
These frequently asked questions give patients and their families information about the services and safeguards we use for our web-based symptom...
Guidelines and Advice
Status: Current
ID: GL-C50-15
Jun 2014
Drug
Other Name(s): Kadcyla®
Aug 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Emtansine - Unresectable Locally Advanced or Metastatic Breast Cancer
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Jan 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Document

Pages